Must-Read Allergy & Immunology Research Articles: 2011
Must-Read Allergy & Immunology Research Articles: 2011
Of the thousands of research articles published worldwide each year in the field of allergy and clinical immunology, it's hard to choose which articles were the most important of 2011. To narrow down the field, Medscape Allergy & Clinical Immunology asked our board members and contributors to pick 2 or 3 research articles that resonated with them over the past year.
Here are their selections:
In this study, Saini and colleagues found that one 300 mg dose of omalizumab reduced itch and hive scores in patients with chronic idiopathic urticaria.
"It's a small study but the first drug to show promise in a common and frustrating disease," said Medscape Allergy & Clinical Immunology blogger Gary Stadtmauer, MD.
"When antihistamines are ineffective, the only drugs that work reliably are fairly toxic," said Stadtmauer, who blogged about the study here.
Abstract
Introduction
Of the thousands of research articles published worldwide each year in the field of allergy and clinical immunology, it's hard to choose which articles were the most important of 2011. To narrow down the field, Medscape Allergy & Clinical Immunology asked our board members and contributors to pick 2 or 3 research articles that resonated with them over the past year.
Here are their selections:
A Randomized, Placebo-Controlled, Dose-Ranging Study of Single-Dose Omalizumab in Patients with H1-Antihistamine-Refractory Chronic Idiopathic Urticaria
In this study, Saini and colleagues found that one 300 mg dose of omalizumab reduced itch and hive scores in patients with chronic idiopathic urticaria.
"It's a small study but the first drug to show promise in a common and frustrating disease," said Medscape Allergy & Clinical Immunology blogger Gary Stadtmauer, MD.
"When antihistamines are ineffective, the only drugs that work reliably are fairly toxic," said Stadtmauer, who blogged about the study here.
Abstract